ITP caused by immune checkpoint inhibitors (ICIs) is rare (0.25% incidence) but generally has a good prognosis. Most patients respond to standard first-line ITP therapies, and approximately 70% of those re-challenged with the ICI can continue treatment without a recurrence of ITP.

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

In the VEHAT-two trial for ITP, 8% of patients receiving a placebo infusion experienced an infusion reaction. This surprising finding underscores the necessity of placebo-controlled studies to differentiate true drug-related adverse events from effects caused by the procedure or patient expectation.

Beyond raising platelet counts, the newly approved BTK inhibitor rilzabrutinib provides dramatic improvements in the fatigue associated with ITP. This unique benefit, likely due to its anti-inflammatory properties, makes it a strong consideration for patients where fatigue is a primary quality of life issue.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

The LUNA-three trial demonstrated that ITP patients on rilzabrutinib showed improved fatigue. Notably, even patients whose platelet counts did not respond to the drug still had better fatigue outcomes than the placebo group, suggesting a separate anti-inflammatory benefit on quality of life.

Named after the two-faced god Janus, yanalumab has a dual mechanism. It acts as a highly potent B-cell depleter while also blocking the BAF receptor pathway, which is critical for auto-reactive B-cell survival. This offers potential for deep, lasting, treatment-free remission.